Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Перспективы изотретиноина в терапии торпидных форм акне
Перспективы изотретиноина в терапии торпидных форм акне
Дворянкова Е.В., Голембиовская И.В., Сакания Л.Р., Корсунская И.М. Перспективы изотретиноина в терапии торпидных форм акне. Consilium Medicum. Дерматология (Прил.). 2015; 3: 16–19.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В работе приводятся основные сведения о применении системных ретиноидов в терапии тяжелых форм акне, отмечены основные негативные эффекты при назначении данной группы препаратов. Описаны механизмы действия изотретиноина на патогенез акне. Также представлены собственные наблюдения, позволяющие достигнуть кумулятивной дозы препарата с наименьшими отрицательными клиническими проявлениями.
Ключевые слова: изотретиноин, акне, тяжелые формы.
Ключевые слова: изотретиноин, акне, тяжелые формы.
________________________________________________
Полный текст
Список литературы
1. Patton TJ, Zirwas MJ, Wolverton SE. Systemic retinoids. In: Wolverton SE, editor. Comprehensive Dermatologic Drug Therapy. 2nd ed. Philadelphia: Saunders-Elsevier, 2007; p. 275–300.
2. Cryulnik AA, Viola KV, Gewirtzman AJ et al. High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life. Int J Dermatol 2012; 51: 1123–30.
3. Stainforth JM, Layton AM, Taylor JP et al. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br J Dermatol 1993; 129: 297–301.
4. Lehucher CD, De la Salmoniere P et al. Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology 1999; 198: 278–83.
5. Strauss JS, Rapini RP, Shalita AR et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 1984; 10 (3): 490–6.
6. Colburn WA, Gibson DM, Wiens RE, Hanigan JJ. Food increases the bioavailability of isotretinoin. J Clin Pharmacol 1983; 23: 534–9.
7. Strauss JS, Krowchuk DP, Leyden JJ et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007; 56 (4): 651–63.
8. White GM, Chen W. Recurrence rates after first course of isotretinoin. Arch Dermatol 1998; 134: 376–78.
9. Layton A. The use of isotretinoin in acne. Dermatoendocrinology 2009; 1 (3): 162–9.
10. Nelson AM, Zhao W, Gilliland KL et al. Neutrophil gelatinase-associated lipocalin mediates 13-cis retinoic acid-induced apoptosis of human sebaceous gland cells. J Clin Investig 2008; 118: 1468–78.
11. Ward A, Brogden RN, Heel RC et al. Isotretinoin: a review of its pharmacologic properties and therapeutic efficacy in acne and other skin disorders. Drugs 1984; 28: 6–37.
12. Dispenza MC, Wolpert EB, Gilliland KL et al. Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol 2012; 132: 2198–205.
13. Colburn WA, Gibson DM, Wiens RE, Hanigan JJ. Food increases the bioavailability of isotretinoin. J Clin Pharmacol 1983; 23: 534–9.
14. Кочергин Н.А., Самгин М.А., Монахов С.А., Игнатьев Д. Дерматологический индекс акне. Эстетическая медицина. 2004; 3 (1): 62–5. / Kochergin N.A., Samgin M.A., Monakhov S.A., Ignat'ev D. Dermatologicheskii indeks akne. Esteticheskaia meditsina. 2004; 3 (1): 62–5. [in Russian]
2. Cryulnik AA, Viola KV, Gewirtzman AJ et al. High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life. Int J Dermatol 2012; 51: 1123–30.
3. Stainforth JM, Layton AM, Taylor JP et al. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br J Dermatol 1993; 129: 297–301.
4. Lehucher CD, De la Salmoniere P et al. Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology 1999; 198: 278–83.
5. Strauss JS, Rapini RP, Shalita AR et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 1984; 10 (3): 490–6.
6. Colburn WA, Gibson DM, Wiens RE, Hanigan JJ. Food increases the bioavailability of isotretinoin. J Clin Pharmacol 1983; 23: 534–9.
7. Strauss JS, Krowchuk DP, Leyden JJ et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007; 56 (4): 651–63.
8. White GM, Chen W. Recurrence rates after first course of isotretinoin. Arch Dermatol 1998; 134: 376–78.
9. Layton A. The use of isotretinoin in acne. Dermatoendocrinology 2009; 1 (3): 162–9.
10. Nelson AM, Zhao W, Gilliland KL et al. Neutrophil gelatinase-associated lipocalin mediates 13-cis retinoic acid-induced apoptosis of human sebaceous gland cells. J Clin Investig 2008; 118: 1468–78.
11. Ward A, Brogden RN, Heel RC et al. Isotretinoin: a review of its pharmacologic properties and therapeutic efficacy in acne and other skin disorders. Drugs 1984; 28: 6–37.
12. Dispenza MC, Wolpert EB, Gilliland KL et al. Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol 2012; 132: 2198–205.
13. Colburn WA, Gibson DM, Wiens RE, Hanigan JJ. Food increases the bioavailability of isotretinoin. J Clin Pharmacol 1983; 23: 534–9.
14. Kochergin N.A., Samgin M.A., Monakhov S.A., Ignat'ev D. Dermatologicheskii indeks akne. Esteticheskaia meditsina. 2004; 3 (1): 62–5. [in Russian]
2. Cryulnik AA, Viola KV, Gewirtzman AJ et al. High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life. Int J Dermatol 2012; 51: 1123–30.
3. Stainforth JM, Layton AM, Taylor JP et al. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br J Dermatol 1993; 129: 297–301.
4. Lehucher CD, De la Salmoniere P et al. Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology 1999; 198: 278–83.
5. Strauss JS, Rapini RP, Shalita AR et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 1984; 10 (3): 490–6.
6. Colburn WA, Gibson DM, Wiens RE, Hanigan JJ. Food increases the bioavailability of isotretinoin. J Clin Pharmacol 1983; 23: 534–9.
7. Strauss JS, Krowchuk DP, Leyden JJ et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007; 56 (4): 651–63.
8. White GM, Chen W. Recurrence rates after first course of isotretinoin. Arch Dermatol 1998; 134: 376–78.
9. Layton A. The use of isotretinoin in acne. Dermatoendocrinology 2009; 1 (3): 162–9.
10. Nelson AM, Zhao W, Gilliland KL et al. Neutrophil gelatinase-associated lipocalin mediates 13-cis retinoic acid-induced apoptosis of human sebaceous gland cells. J Clin Investig 2008; 118: 1468–78.
11. Ward A, Brogden RN, Heel RC et al. Isotretinoin: a review of its pharmacologic properties and therapeutic efficacy in acne and other skin disorders. Drugs 1984; 28: 6–37.
12. Dispenza MC, Wolpert EB, Gilliland KL et al. Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol 2012; 132: 2198–205.
13. Colburn WA, Gibson DM, Wiens RE, Hanigan JJ. Food increases the bioavailability of isotretinoin. J Clin Pharmacol 1983; 23: 534–9.
14. Кочергин Н.А., Самгин М.А., Монахов С.А., Игнатьев Д. Дерматологический индекс акне. Эстетическая медицина. 2004; 3 (1): 62–5. / Kochergin N.A., Samgin M.A., Monakhov S.A., Ignat'ev D. Dermatologicheskii indeks akne. Esteticheskaia meditsina. 2004; 3 (1): 62–5. [in Russian]
________________________________________________
2. Cryulnik AA, Viola KV, Gewirtzman AJ et al. High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life. Int J Dermatol 2012; 51: 1123–30.
3. Stainforth JM, Layton AM, Taylor JP et al. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br J Dermatol 1993; 129: 297–301.
4. Lehucher CD, De la Salmoniere P et al. Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology 1999; 198: 278–83.
5. Strauss JS, Rapini RP, Shalita AR et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 1984; 10 (3): 490–6.
6. Colburn WA, Gibson DM, Wiens RE, Hanigan JJ. Food increases the bioavailability of isotretinoin. J Clin Pharmacol 1983; 23: 534–9.
7. Strauss JS, Krowchuk DP, Leyden JJ et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007; 56 (4): 651–63.
8. White GM, Chen W. Recurrence rates after first course of isotretinoin. Arch Dermatol 1998; 134: 376–78.
9. Layton A. The use of isotretinoin in acne. Dermatoendocrinology 2009; 1 (3): 162–9.
10. Nelson AM, Zhao W, Gilliland KL et al. Neutrophil gelatinase-associated lipocalin mediates 13-cis retinoic acid-induced apoptosis of human sebaceous gland cells. J Clin Investig 2008; 118: 1468–78.
11. Ward A, Brogden RN, Heel RC et al. Isotretinoin: a review of its pharmacologic properties and therapeutic efficacy in acne and other skin disorders. Drugs 1984; 28: 6–37.
12. Dispenza MC, Wolpert EB, Gilliland KL et al. Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol 2012; 132: 2198–205.
13. Colburn WA, Gibson DM, Wiens RE, Hanigan JJ. Food increases the bioavailability of isotretinoin. J Clin Pharmacol 1983; 23: 534–9.
14. Kochergin N.A., Samgin M.A., Monakhov S.A., Ignat'ev D. Dermatologicheskii indeks akne. Esteticheskaia meditsina. 2004; 3 (1): 62–5. [in Russian]
Авторы
Е.В.Дворянкова1, И.В.Голембиовская2, Л.Р.Сакания1, И.М.Корсунская*1
1. ФГБУН Центр теоретических проблем физико-химической фармакологии РАН. 119991, Россия, Москва, Ленинский пр-т, д. 38а, корп. 1;
2. ФГАОУ ВО Российский университет дружбы народов. 117198, Россия, Москва, ул. Миклухо-Маклая, д. 6
*marykor@bk.ru
1. Center for Theoretical Problems of Physicochemical Pharmacology. 119991, Russian Federation, Moscow, Leninskiy pr-t, d. 38a, korp. 1;
2. People’s Friendship University of Russia. 117198, Russian Federation, Moscow, ul. Miklukho-Maklaia, d. 6
*marykor@bk.ru
1. ФГБУН Центр теоретических проблем физико-химической фармакологии РАН. 119991, Россия, Москва, Ленинский пр-т, д. 38а, корп. 1;
2. ФГАОУ ВО Российский университет дружбы народов. 117198, Россия, Москва, ул. Миклухо-Маклая, д. 6
*marykor@bk.ru
________________________________________________
1. Center for Theoretical Problems of Physicochemical Pharmacology. 119991, Russian Federation, Moscow, Leninskiy pr-t, d. 38a, korp. 1;
2. People’s Friendship University of Russia. 117198, Russian Federation, Moscow, ul. Miklukho-Maklaia, d. 6
*marykor@bk.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.